The Purinergic System As a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases

Overview

Journal Pharmacol Rev

Specialty Pharmacology

Date 2019 Jun 26

PMID 31235653

Citations 82

Authors

Luca Antonioli

Corrado Blandizzi

Pal Pacher

Gyorgy Hasko

Affiliations

Soon will be listed here.

Abstract

Immune-mediated inflammatory diseases (IMIDs) encompass a wide range of seemingly unrelated conditions, such as multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, asthma, chronic obstructive pulmonary disease, and systemic lupus erythematosus. Despite differing etiologies, these diseases share common inflammatory pathways, which lead to damage in primary target organs and frequently to a plethora of systemic effects as well. The purinergic signaling complex comprising extracellular nucleotides and nucleosides and their receptors, the P2 and P1 purinergic receptors, respectively, as well as catabolic enzymes and nucleoside transporters is a major regulatory system in the body. The purinergic signaling complex can regulate the development and course of IMIDs. Here we provide a comprehensive review on the role of purinergic signaling in controlling immunity, inflammation, and organ function in IMIDs. In addition, we discuss the possible therapeutic applications of drugs acting on purinergic pathways, which have been entering clinical development, to manage patients suffering from IMIDs.

Citing Articles

P2Y6R Inhibition Induces Microglial M2 Polarization by Promoting PINK1/Parkin-Dependent Mitophagy After Spinal Cord Injury.

Lin J, Sun Y, Huang H, Yu C, Kuang W, Wang Y Mol Neurobiol. 2024; .

PMID: 39607640 DOI: 10.1007/s12035-024-04631-5.

Macrophage P2YR activation aggravates psoriatic inflammation through IL-27-mediated Th1 responses.

Yin L, Zhang E, Mao T, Zhu Y, Ni S, Li Y Acta Pharm Sin B. 2024; 14(10):4360-4377.

PMID: 39525587 PMC: 11544167. DOI: 10.1016/j.apsb.2024.06.008.

Trifluoro-Icaritin Ameliorates Neuroinflammation Against Complete Freund's Adjuvant-Induced Microglial Activation by Improving CB2 Receptor-Mediated IL-10/β-endorphin Signaling in the Spinal Cord of Rats.

Liu G, Jia D, Li W, Huang Z, Shan R, Huang C J Neuroimmune Pharmacol. 2024; 19(1):53.

PMID: 39387998 DOI: 10.1007/s11481-024-10152-8.

Current treatment of Psoriasis triggered by Cytokine Storm and future immunomodulation strategies.

Braga G, Francisco G, Bagatini M J Mol Med (Berl). 2024; 102(10):1187-1198.

PMID: 39212718 DOI: 10.1007/s00109-024-02481-1.

A non-targeted metabolomics comparative study on plasma of pfizer and sinopharm COVID-19 vaccinated individuals, assessed by (TIMS-QTOF) mass spectrometry.

Abufares H, Zenati R, Soares N, El-Huneidi W, Dahabiyeh L, Al-Hroub H Heliyon. 2024; 10(15):e35443.

PMID: 39170395 PMC: 11336712. DOI: 10.1016/j.heliyon.2024.e35443.

References

Samuraki M, Sakai K, Odake Y, Yoshita M, Misaki K, Nakada M . Multiple sclerosis showing elevation of adenosine deaminase levels in the cerebrospinal fluid. Mult Scler Relat Disord. 2017; 13:44-46. DOI: 10.1016/j.msard.2017.02.005. View

Wang L, Tang P, Shi C, Wan Y, Tang W, Hou X . Expression of CD39 mRNA is altered in the peripheral blood of patients with allergic asthma. Biomed Rep. 2014; 2(1):75-78. PMC: 3917046. DOI: 10.3892/br.2013.196. View

Boldrini L, Giordano M, Ali G, Melfi F, Romano G, Lucchi M . P2X7 mRNA expression in non-small cell lung cancer: MicroRNA regulation and prognostic value. Oncol Lett. 2014; 9(1):449-453. PMC: 4247004. DOI: 10.3892/ol.2014.2620. View

Burnstock G . The therapeutic potential of purinergic signalling. Biochem Pharmacol. 2017; 151:157-165. DOI: 10.1016/j.bcp.2017.07.016. View

Antonioli L, Colucci R, Pellegrini C, Giustarini G, Tuccori M, Blandizzi C . The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications. Pharmacol Ther. 2013; 139(2):157-88. DOI: 10.1016/j.pharmthera.2013.04.002. View

Vivekanandhan S, Soundararajan C, Tripathi M, Maheshwari M . Adenosine deaminase and 5'nucleotidase activities in peripheral blood T cells of multiple sclerosis patients. Neurochem Res. 2005; 30(4):453-6. DOI: 10.1007/s11064-005-2680-6. View

Chen M, Liang D, Zuo A, Shao H, Kaplan H, Sun D . An A2B Adenosine Receptor Agonist Promotes Th17 Autoimmune Responses in Experimental Autoimmune Uveitis (EAU) via Dendritic Cell Activation. PLoS One. 2015; 10(7):e0132348. PMC: 4492970. DOI: 10.1371/journal.pone.0132348. View

Naganuma M, Wiznerowicz E, Lappas C, Linden J, Worthington M, Ernst P . Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J Immunol. 2006; 177(5):2765-9. DOI: 10.4049/jimmunol.177.5.2765. View

Berner B, Wolf G, Hummel K, Muller G, Reuss-Borst M . Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis. Ann Rheum Dis. 2000; 59(3):190-5. PMC: 1753086. DOI: 10.1136/ard.59.3.190. View

10.

Varani K, Caramori G, Vincenzi F, Tosi A, Barczyk A, Contoli M . Oxidative/nitrosative stress selectively altered A(2B) adenosine receptors in chronic obstructive pulmonary disease. FASEB J. 2009; 24(4):1192-204. DOI: 10.1096/fj.09-139485. View

11.

Blackburn M, Volmer J, Thrasher J, Zhong H, Crosby J, Lee J . Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J Exp Med. 2000; 192(2):159-70. PMC: 2193256. DOI: 10.1084/jem.192.2.159. View

12.

Fulzele S, El-Sherbini A, Ahmad S, Sangani R, Matragoon S, El-Remessy A . MicroRNA-146b-3p regulates retinal inflammation by suppressing adenosine deaminase-2 in diabetes. Biomed Res Int. 2015; 2015:846501. PMC: 4359882. DOI: 10.1155/2015/846501. View

13.

La Motta C, Sartini S, Mugnaini L, Salerno S, Simorini F, Taliani S . Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors. J Med Chem. 2009; 52(6):1681-92. DOI: 10.1021/jm801427r. View

14.

Antonioli L, Fornai M, Awwad O, Giustarini G, Pellegrini C, Tuccori M . Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats. Br J Pharmacol. 2013; 171(5):1314-29. PMC: 3952807. DOI: 10.1111/bph.12539. View

15.

Hasko G, Pacher P . Regulation of macrophage function by adenosine. Arterioscler Thromb Vasc Biol. 2012; 32(4):865-9. PMC: 3387535. DOI: 10.1161/ATVBAHA.111.226852. View

16.

Garzon R, Marcucci G, Croce C . Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10):775-89. PMC: 3904431. DOI: 10.1038/nrd3179. View

17.

Ingwersen J, Wingerath B, Graf J, Lepka K, Hofrichter M, Schroter F . Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation. J Neuroinflammation. 2016; 13:48. PMC: 4768407. DOI: 10.1186/s12974-016-0512-z. View

18.

Idzko M, Hammad H, van Nimwegen M, Kool M, Willart M, Muskens F . Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med. 2007; 13(8):913-9. DOI: 10.1038/nm1617. View

19.

Ochaion A, Bar-Yehuda S, Cohen S, Amital H, Jacobson K, Joshi B . The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochem Pharmacol. 2008; 76(4):482-94. PMC: 2677448. DOI: 10.1016/j.bcp.2008.05.032. View

20.

Szabo C, Scott G, Virag L, Egnaczyk G, Salzman A, Shanley T . Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol. 1998; 125(2):379-87. PMC: 1565610. DOI: 10.1038/sj.bjp.0702040. View